EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Identification of factors conferring resistance to trastuzumab deruxtecan in advanced gastric cancer: a translational study from the single-arm, phase II, DESTINY-Gastric06 trial

Bohan Zhang, Lei Zhang, Cheng Liu, Tong Xie, Yifan Zhang, Xiao Wu, Yining Chen, Siyuan Cheng, Yang Feng, Yuxin Wang, Erke Gao, Hongquan Zhang iD und 3 weitere

Precision Clinical Medicine · 30.01.2026 · 9 (1)

DOI: 10.1093/pcmedi/pbaf038 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Precision Clinical Medicine, online erschienen am 19.12.2025. Verfasst von Bohan Zhang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Oncology, Peking University Cance…. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Beijing Xisike Clinical Oncology Research Foundation, Beijing Natural Science Foundation, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Trastuzumab deruxtecan (T-DXd) has revolutionized the therapeutic landscape for HER2-positive gastric cancer (GC). However, tumor heterogeneity poses a significant challenge in overcoming T-DXd resistance. This study aimed to delineate the mechanisms underlying primary and acquired resistance to T-DXd in GC.

Methods

We performed single-cell RNA sequencing on GC tumor tissues from the DESTINY-Gastric06 study, including treatment-naive baseline samples and those with primary or acquired resistance to T-DXd. Dimensionality reduction and unsupervised clustering were applied to identify distinct cell clusters within the tumor tissues. High-dimensional weighted gene co-expression network analysis was employed to identify key gene modules associated with T-DXd resistance. Cell–cell communication was analyzed using CellChat. Key findings were experimentally validated through multiplex immunofluorescence, immunohistochemistry, and functional assays in cellular models.

Results

Weighted gene co-expression network analysis identified the red and purple modules as being strongly correlated with primary and acquired T-DXd resistance, respectively. Notably, MUC3A was upregulated in patients with primary resistance and its overexpression was identified as a potential predictor of shorter progression-free survival in response to T-DXd therapy. Moreover, cystatin C, a gene implicated in linker cleavage, was upregulated during the development of acquired resistance. Tumor microenvironment profiling revealed that T-DXd initially promoted immune-cell infiltration and enhanced antigen presentation. However, with the development of resistance, the tumor microenvironment shifted to an immunosuppressive state, characterized by reactivation of transforming growth factor-beta signaling and upregulation of programmed cell death protein-1 (PD-1).

Conclusion

These findings provide novel insights into mechanisms underlying T-DXd resistance and highlight potential therapeutic targets for overcoming T-DXd resistance in GC.

Schlagwörter

Stichwörter der Autor:innen

gastric cancerresistancetrastuzumab deruxtecan

Autor:innen und Institutionen

  • Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China.
  • Department of medical and marketing, Burning Rock Biotech, Guangzhou 510300, China.
  • Department of Human Anatomy, Histology and Embryology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China.
  • Peking University International Cancer Institute, Peking University Health Science Center, Beijing 100191, China.
  • State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Gastrointestinal Oncology, Peking University Cancer…

ORCID-Profile: Hongquan Zhang, Lin Shen

Förderung

  • Beijing Xisike Clinical Oncology Research Foundation
  • Beijing Natural Science Foundation
  • National Natural Science Foundation of China

Zitieren

APA

Zhang, B., Zhang, L., Liu, C., Xie, T., Zhang, Y., Wu, X., Chen, Y., Cheng, S., Feng, Y., Wang, Y., Gao, E., Zhang, H., Shen, L., Peng, Z., & Wei, X. (2026). Identification of factors conferring resistance to trastuzumab deruxtecan in advanced gastric cancer: a translational study from the single-arm, phase II, DESTINY-Gastric06 trial. Precision Clinical Medicine, 9(1). https://doi.org/10.1093/pcmedi/pbaf038

Vancouver

Zhang B, Zhang L, Liu C, Xie T, Zhang Y, Wu X, et al. Identification of factors conferring resistance to trastuzumab deruxtecan in advanced gastric cancer: a translational study from the single-arm, phase II, DESTINY-Gastric06 trial. Precision Clinical Medicine. 2026;9(1). doi:10.1093/pcmedi/pbaf038

BibTeX
@article{Zhang2026,
  author = {Zhang, Bohan and Zhang, Lei and Liu, Cheng and Xie, Tong and Zhang, Yifan and Wu, Xiao and Chen, Yining and Cheng, Siyuan and Feng, Yang and Wang, Yuxin and Gao, Erke and Zhang, Hongquan and Shen, Lin and Peng, Zhi and Wei, Xiaofan},
  title = {Identification of factors conferring resistance to trastuzumab deruxtecan in advanced gastric cancer: a translational study from the single-arm, phase II, DESTINY-Gastric06 trial},
  journal = {Precision Clinical Medicine},
  year = {2026},
  volume = {9},
  number = {1},
  doi = {10.1093/pcmedi/pbaf038}
}
Kostenlos starten →